Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02265510 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT02265510 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 83 participants.
The verdict
NCT02265510, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).
Interventions
- DRUG nab-paclitaxel
- DRUG Carfilzomib
- DRUG dexamethasone
- DRUG gemcitabine
- DRUG INCB052793
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2014-09-10 |
| Est. Completion | 2019-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02265510
The ClinicalTrials.gov registry entry for NCT02265510 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which nab-paclitaxel is the first listed.
NCT02265510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02265510 about?
NCT02265510 is a clinical study titled "An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies". This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a d...
What is the current status of trial NCT02265510?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2014-09-10. Estimated completion is 2019-02-27.
What interventions are being tested in trial NCT02265510?
The interventions under investigation include: nab-paclitaxel (DRUG), Carfilzomib (DRUG), dexamethasone (DRUG), gemcitabine (DRUG), INCB052793 (DRUG).
Who is sponsoring clinical trial NCT02265510?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.